Immune Regulation

Immune Regulation Overview

Founded 2011
Founded
Status Private
Latest Deal Type Later Stage VC
Latest Deal Amount $5.66M
Latest Deal Amount
Investors 3

Immune Regulation General Information

Description

Developer of anti-inflammatory peptides designed to treat immuno-inflammatory diseases resulting from a poorly controlled or overactive immune response. The company's peptides have the ability to significantly advance the control and management of moderate to severe chronic inflammatory diseases, with the potential for diseases modification and remission, enabling patients with immuno-inflammatory diseases like asthma, atopic dermatitis and inflammatory bowel diseases to get better treatment and faster recovery.

Contact Information

Formerly Known As
Peptinnovate
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Stevenage Bioscience Catalyst, Gunnels Wood Road
  • Hertfordshire
  • Stevenage SG1 2FX
  • England, United Kingdom
+44 01438 000000

Immune Regulation Timeline

2017201820192020
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Immune Regulation Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 16-May-2018 $5.66M 000.00 000.00 Completed Generating Revenue
5. Later Stage VC 14-Jun-2017 00.000 00.00 000.00 Completed Generating Revenue
4. Early Stage VC 23-Feb-2016 00.000 00.000 000.00 Completed Generating Revenue
3. Early Stage VC 28-Jul-2015 00000 00.000 000.00 Completed Generating Revenue
2. Grant $940K Completed Generating Revenue
1. Angel (individual) 17-Dec-2014 $940K $940K 0000 Completed Generating Revenue

Immune Regulation Cap Table

To view Immune Regulation‘s complete cap table, request access >>
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 00,000 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 30,530 $0.000137 $123.68 $123.68 1x $123.68 1.53%

Immune Regulation Executive Team (11)

Name Title Board Seat Contact Info
Richard Nagle Chief Executive Officer & Board Member
Clare Burgess Ph.D Chief Operating Officer
Roly Foulkes Ph.D Co-Chief Scientific Officer
David Beadle Chief Business Officer & Board Member
Jeannette Watson Head of Development

4 Former Executives

Immune Regulation Board Members (11)

To view Immune Regulation‘s full board member team, request access >>
Name Representing Role Since
Anthony Martin Ph.D Immune Regulation Chairman 000 0000
Ben Cons Immune Regulation Board Member 000 0000
Christopher Smith Immune Regulation Board Member 000 0000
Clive Page Immune Regulation Chairman 000 0000
David Beadle Immune Regulation Chief Business Officer & Board Member 000 0000

2 Former Board Members

Immune Regulation Investors (3)

To view Immune Regulation‘s full investor history, request access >>
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
24Haymarket Angel Group Minority 000 0000 000000 0
NCL Technology Ventures Venture Capital Minority 000 0000 000000 0
Metellus Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial